Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Brii Bio In-licenses Seven Anti-Infectives from Three Companies

publication date: Nov 21, 2019

Brii Biosciences, a Shanghai-US anti-infectives company, announced partnerships that add up to seven new compounds to its portfolio, raising its total to twelve in-licensed infectious disease products aimed at China's market. Brii will advance the candidates from clinical proof-of-concept through to commercialization. The new products include a TB treatment from AN2 of Menlo Park, CA; a group of treatments for drug resistant, gram-negative pathogens from Qpex Biopharma of San Diego, CA; and up to three programs from Artizan of New Haven, CT that address inflammatory disease-causing bugs in the gut. More details....

Share this with colleagues:



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital